Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

Journal of Clinical Oncology

Volumn 31, Issue 4, 2013, Pages 482-489

  Kim, Kevin B ^a   Kefford, Richard ^b   Pavlick, Anna C ^e   Infante, Jeffrey R ^f   Ribas, Antoni ^h   Sosman, Jeffrey A ^g   Fecher, Leslie A ⁱ   Millward, Michael ^c   McArthur, Grant A ^d   Hwu, Patrick ^a   Gonzalez, Rene ^k   Ott, Patrick A ^e   Long, Georgina V ^b   Gardner, Olivia S ^j   Ouellet, Daniele ^j   Xu, Yanmei ^j   DeMarini, Douglas J ^j   Le, Ngocdiep T ^j   Patel, Kiran ^j   Lewis, Karl D ^k  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e NEW YORK UNIVERSITY   (United States)

^f SARAH CANNON RESEARCH INSTITUTE   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h UCLA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j GLAXOSMITHKLINE   (United States)

^k UNIVERSITY OF COLORADO CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; IPILIMUMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONSTIPATION; CUTANEOUS MELANOMA; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRY SKIN; FATIGUE; FEMALE; GENE MUTATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN CARCINOMA; SKIN PRURITUS; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; KAPLAN MEIER METHOD; MELANOMA; MIDDLE AGED; MUTATION; PATHOLOGY; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84874777853     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.5966     Document Type: Article

References (31)

1. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147, 2005 (Pubitemid 41653105)
2. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949- 954, 2002 (Pubitemid 34716871)
3. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707- 714, 2012
4. Long GV, Menzies AM, Nagrial AM, et al: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29: 1239-1246, 2011
5. Thomas NE, Edmiston SN, Alexander A, et al: Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 16: 991-997, 2007 (Pubitemid 46910102)
6. Cheng S, Chu P, Hinshaw M, et al: Frequency of mutations associated with targeted therapy in malignant melanoma patients. J Clin Oncol 29:549s, 2011 (suppl; abstr 8597)
7. Jakob JA, Bassett RL Jr, Ng CS, et al: NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118: 4014-4023, 2012
8. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
9. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365, 2012
10. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819, 2010
11. Kirkwood JM, Bastholt L, Robert C, et al: Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 18: 555-567, 2012
12. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16: 1924-1937, 2010
13. Haura EB, Ricart AD, Larson TG, et al: A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 16: 2450-2457, 2010
14. Fedorenko IV, Paraiso KH, Smalley KS: Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 82: 201-209, 2011
15. Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968- 972, 2010
16. Long GV, Wilmott JS, Howle JR, et al: Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi). J Clin Oncol 29:536s, 2011 (suppl; abstr 8542)
17. McArthur GA, Ribas A, Chapman PB, et al: Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutationpositive metastatic melanoma patients (pts). J Clin Oncol 29:526s, 2011 (suppl; abstr 8502)
18. Montagut C, Sharma SV, Shioda T, et al: Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68: 4853-4861, 2008
19. Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977, 2010
20. Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695, 2010
21. Gilmartin AG, Bleam MR, Groy A, et al: GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17: 989-1000, 2011
22. Infante JR, Fecher LA, Falchook GS, et al: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol 13:773- 781, 2012
23. Falchook GS, Lewis KD, Infante JR, et al: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 doseescalation trial. Lancet Oncol 13: 782-789, 2012
24. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107-114, 2012
25. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009
26. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
27. Green SJ, Dahlberg S: Planned versus attained design in phase II clinical trials. Stat Med 11: 853-862, 1992
28. Adjei AA, Cohen RB, Franklin W, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26: 2139-2146, 2008
29. Lorusso PM, Adjei AA, Varterasian M, et al: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23: 5281-5293, 2005 (Pubitemid 46206982)
30. Atefi M, von Euw E, Attar N, et al: Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 6:e28973, 2011
31. Weber JS, Flaherty KT, Infante JR, et al: Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. J Clin Oncol 30:542s, 2012 (suppl; abstr 8510)